Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9450 in chronic hepatitis C
2007-001601-16Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing GS-9450 with Placebo (2 arms). Primary endpoint: Tolerability of multiple oral doses of GS-9450. Started Apr 2007; status: completed.
02
Drugs
nivocasan
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2007-001601-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001601-16.